Experimental vaccine fights rare adrenal cancers
NCT ID NCT04187404
Summary
This study tested a new cancer vaccine called EO2401 combined with an immunotherapy drug for people with advanced adrenal cancers that had spread. The goal was to see if this combination was safe and could help control these rare, aggressive tumors. The trial enrolled 70 adults with specific types of adrenal cancer and was stopped early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, location VUmc
Amsterdam, 1081, Netherlands
-
Assistance Publique - Hôpitaux de Marseille - Hôpital Nord
Marseille, 13915, France
-
Azienda Ospedaliera Spedali Civili
Brescia, 25121, Italy
-
Centre Léon Bérard
Lyon, 69008, France
-
Chu Lille
Lille, 59037, France
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Karolinska University Hospital
Stockholm, 17176, Sweden
-
Lmu Klinikum
München, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Universitätsklinikum Würzburg
Würzburg, 97080, Germany
Conditions
Explore the condition pages connected to this study.